Trials / Active Not Recruiting
Active Not RecruitingNCT04261712
A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)
An Open Label, Long-term Extension Study to Evaluate the Safety and Efficacy of CRN00808 in Subjects With Acromegaly (ACROBAT Advance)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Crinetics Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A phase 2, open label, long-term extension study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with acromegaly.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paltusotine | Paltusotine, once daily by mouth |
Timeline
- Start date
- 2020-01-29
- Primary completion
- 2028-03-01
- Completion
- 2028-03-01
- First posted
- 2020-02-10
- Last updated
- 2026-04-03
Locations
22 sites across 7 countries: United States, Brazil, Germany, Greece, Hungary, Serbia, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04261712. Inclusion in this directory is not an endorsement.